• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Saudi Arabia·Healthcare·9626.SR
Share

Basma Adeem Medical Co. Stocks

SAR 6.06Last Updated 27.07.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Considerable

Recommendation

Hold

Market Cap

SAR 32.29M

SAR 6.06
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Basma Adeem Medical Co. specializes in delivering a broad spectrum of dental and dermatological services. Their extensive medical offerings encompass various procedures, including outpatient (one-day) surgery, orthodontic treatments, and advanced maxillofacial surgery. Within dentistry, they provide periodontal surgery, dental implants, root canal therapy (endodontics), general oral and dental health services, and a wide array of restorative, cosmetic, and prosthodontic dental solutions, alongside dedicated pediatric dentistry. Additionally, the company offers comprehensive dermatology and laser treatments. Founded on November 13, 2012, its operations are headquartered in Riyadh, Saudi Arabia.

Company Valuation

Undervalued
6/7

Based on key historical and expected multiples, the stock is undervalued relative to its peers. In particular, the stock is underpriced on P/E, 'cheap' on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

28.07.2026 22:21

Apple's market capitalization reached $5 trillion for the first time

28.07.2026 22:17

The EU is preparing a record-breaking package of sanctions against more than 1,600 Russian companies — media reports

28.07.2026 22:14

Boeing's loss was worse than expected. Why are its shares rising?

28.07.2026 21:58

U.S. senators have agreed on “severe sanctions” against Russia. What happens next?

28.07.2026 21:28

Apple Is Preparing for a Breakthrough in the Smart Home Market — Bloomberg

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026